Smoking History and Cognitive Function in Middle Age from the Whitehall II Study
Overview
Affiliations
Background: Studies about the association between smoking and dementia necessarily involve those who have "survived" smoking. We examine the association between smoking history and cognitive function in middle age and estimate the risk of death and of nonparticipation in cognitive tests among smokers.
Methods: Data are from the Whitehall II study of 10,308 participants aged 35 to 55 years at baseline (phase 1 [1985-1988]). Smoking history was assessed at phase 1 and at phase 5 (1997-1999). Cognitive data (memory, reasoning, vocabulary, and semantic and phonemic fluency) were available for 5388 participants at phase 5; 4659 of these were retested 5 years later.
Results: Smokers at phase 1 were at higher risk of death (hazard ratio [HR], 2.00; 95% confidence interval [CI], 1.58-2.52 among men and HR, 2.46; 95% CI, 1.80-3.37 among women) and of nonparticipation in cognitive tests (odds ratio [OR], 1.32; 95% CI, 1.16-1.51 among men and OR, 1.69; 95% CI, 1.41- 2.02 among women). At phase 5 in age- and sex-adjusted analyses, smokers compared with those who never smoked were more likely to be in the lowest quintile of cognitive performance. After adjustment for multiple covariates, this risk remained for memory (OR, 1.37; 95% CI, 1.10-1.73). Ex-smokers at phase 1 had a 30% lower risk of poor vocabulary and low verbal fluency. In longitudinal analysis, the evidence for an association between smoking history and cognitive decline was inconsistent. Stopping smoking during the follow-up period was associated with improvement in other health behaviors.
Conclusions: Smoking was associated with greater risk of poor memory. Middle-aged smokers are more likely to be lost to follow-up by death or through nonparticipation in cognitive tests. Ex-smokers had a lower risk of poor cognition, possibly owing to improvement in other health behaviors.
Zhang J, Wu Z, Tan W, Liu D, Cheng G, Xu L Front Aging Neurosci. 2023; 15:1200671.
PMID: 37600519 PMC: 10438989. DOI: 10.3389/fnagi.2023.1200671.
Ling Y, Guo Q, Wang S, Zhang L, Chen J, Liu Y Parkinsons Dis. 2022; 2022:6915627.
PMID: 36483978 PMC: 9726266. DOI: 10.1155/2022/6915627.
Raggi M, Dugravot A, Valeri L, Machado-Fragua M, Dumurgier J, Kivimaki M Lancet Reg Health Eur. 2022; 23:100516.
PMID: 36189426 PMC: 9523395. DOI: 10.1016/j.lanepe.2022.100516.
Di Tella S, Lo Monaco M, Petracca M, Zinzi P, Solito M, Piano C J Neurol. 2022; 269(12):6634-6640.
PMID: 35915275 DOI: 10.1007/s00415-022-11297-3.
Kim J, Chang I, Kim Y, Min C, Yoo D, Choi H Front Neurol. 2022; 13:810830.
PMID: 35572934 PMC: 9099047. DOI: 10.3389/fneur.2022.810830.